PARIS, April 6, 2009— Nanobiotix, an emerging nanomedicine company, announced that an independent preclinical study has validated the applicability of using its nanoparticles—nanoPDT—to treat glioblastoma multiforme, one of the most prevalent brain tumors. Nanobiotix expects to attract corporate partners for the development of nanoPDT as the Company focuses development efforts on its nanoXray technology... Nanobiotix's Press Release -...
About Nanobiotix
Nanobiotix is a nanomedicine company that intends to revolutionize radiotherapy, making it more deadly to tumors while preserving the surrounding healthy tissues.
The company is a spin-off of the State University of New York (SUNY) at Buffalo that has been incorporated in 2003 and has been primarily funded by leading European venture capital firms (Matignon Technologies, OTC Asset Management, Cap Decisif, Amorcage Rhone-Alpes).
Cancer is now becoming the leading cause of mortality in developing countries. Radiotherapy is the most common tool for cancer treatment and is used in 5,000,000 patients every year (representing 60% of total cancer patients)... more about Nanobiotix -
